Development of cancer vaccine therapy targeting individual genetic mutations identified by next generation sequencing
| Project/Area Number |
24659625
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
NAKAJIMA Jun 東京大学, 医学部附属病院, 教授 (90188954)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MURAKAWA Tomohiro 東京大学, 医学部附属病院, 講師 (50359626)
SANO Atsushi 東京大学, 医学部附属病院, 登録研究員 (20569834)
KAKIMI Kazuhiro 東京大学, 医学部附属病院, 特任教授 (80273358)
MATSUSHITA Hirokazu 東京大学, 医学部附属病院, 特任講師 (80597782)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 肺がん / 次世代シーケンス / 遺伝子変異 / MHCクラスＩ結合予測法 / 固有抗原 / 変異ペプチド / 免疫反応 / 個別化がん免疫治療 / 肺癌 / 膵臓癌 / 全エクソームシーケンス / 全ＲＮＡシーケンス / ミスセンス変異 / 膵がん / 全RNAシーケンス / RNAシーケンス / エクソームシーケンス |
|---|
| Outline of Final Research Achievements |
We established the method to identify candidate unique antigens from cancer specific mutations in pancreatic cancer specimens by combining next generation sequencing with MHC class I binding algorism. We also developed an assay to verify immune responses against those candidate unique antigens in mice. In total 6 lung cancer patients consisting of 3 smokers and 3 non-smokers, the numbers of genetic mutations (missense mutations) were 280 on average in former versus 75 in latter. Accordingly, the numbers of candidate unique antigen-derived T cell epitopes predicted by the algorism were 535 on average in former versus 140 in latter. We successfully created the system predicting candidate unique antigens and verifying them, which is a prerequisite for individualized cancer immunotherapy development in lung cancer patients.
|
Report
(4 results)
Research Products
(22 results)
-
-
-
-
-
-
-
[Journal Article] High-grade Lung Adenocarcinoma With Fetal Lung-like Morphology: Clinicopathologic, Immunohistochemical, and Molecular Analyses of 17 Cases2013
Author(s)
Morita S, Yoshida A, Goto A, Ota S, Tsuta K, Yokozawa K, Asamura H, Nakajima J, Takai D, Mori M, Oka T, Tamaru J, Itoyama S, Furuta K, Fukayama M, Tsuda H.
-
Journal Title
Am J Surg Pathol
Volume: 37(6)
Issue: 6
Pages: 924-932
DOI
Related Report
Peer Reviewed
-
[Journal Article] FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer.2013
Author(s)
Kawakami M, Morita S, Sunohara M, Amano Y, Ishikawa R, Watanabe K, Hamano E, Ohishi N, Nakajima J, Yatomi Y, Nagase T, Fukayama M, Takai D.
-
Journal Title
Int J Clin Exp Pathol
Volume: 6
Pages: 598-612
Related Report
Peer Reviewed
-
-
-
-
[Presentation] 肺癌に対する免疫療法2015
Author(s)
中島 淳
Organizer
4月度 香川県内科医会呼吸器疾患談話会
Place of Presentation
香川県社会福祉総合センター（香川県高松市番町）
Year and Date
2015-04-23
Related Report
Invited
-
-
-
-
-
-
-
-
-
-
